Spinocerebellar Degeneration Clinical Trial
Official title:
An Open-label, Phase II Study of KPS-0373 in Patients With SCD
To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01970098 -
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
Phase 3 | |
Completed |
NCT02889302 -
An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
Phase 3 | |
Completed |
NCT04107740 -
C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
|
Phase 4 | |
Completed |
NCT01970111 -
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
Phase 3 | |
Completed |
NCT01004016 -
A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
Phase 2 | |
Completed |
NCT01970137 -
A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
Phase 3 | |
Completed |
NCT01970124 -
A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
Phase 3 |